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Abstract
Introduction: Successful treatment of p53 mutant, triple-negative breast cancers (TNBC) remains a daunting
challenge. Doxorubicin (DOXO) and cisplatin (CDDP) are standard-of-care treatments for TNBC, but eventually fail
due to acquired drug resistance and toxicity. New treatments for overcoming drug resistance and toxicity in p53
mutant, TNBC are therefore badly needed. Unlike p53, p73 - a member of the p53 family - is usually not mutated
in cancers and has been shown to regulate p53-mediated apoptotic signaling in p53-deficient cancers. Therefore,
identification of anticancer agents that can activate p73 in p53-deficient cancers may provide a chemotherapeutic
approach for treatment of p53 mutant cancers. Here we report on the reconstitution of the p53 tumor suppressor
pathway in a p53-independent manner via p73 with combination treatments of a-TEA, a small bioactive lipid, plus
DOXO or CDDP.
Methods: p53 mutant, TNBC cell lines MDA-MB-231, BT-20 and MDA-MB-468 were used to evaluate the anticancer
effect of chemotherapeutic drugs and a-TEA using annexin V (FITC)/PI staining, western blot analyses, RT-PCR and
siRNA knockdown techniques.
Results: Combination treatments of a-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8
and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53
downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear
translocation - plus reduce expression of Bcl-2. Knockdown of p73, c-Abl, JNK or Yap using siRNAs shows that p73
plays a critical role in combination treatment-enhanced apoptosis and the expression of pro-apoptotic and anti-
apoptotic mediators, and that c-Abl, JNK and Yap are upstream mediators of p73 in combination treatment
responses.
Conclusions: Data show that a-TEA in combination with DOXO or CDDP synergistically enhances apoptosis in
TNBC via targeting p53-mediated genes in a p73-dependent manner, and that p73 responses are downstream of
c-Abl, JNK and Yap.
Introduction
Successful treatment of triple-negative breast cancers
(TNBC) (estrogen receptor (ER)-negative, progesterone
receptor-negative and Her-2-negative), that are also p53
mutant remains elusive. Unfortunately, the anticancer
efficacy of commonly used chemotherapeutic agents for
TNBC, including doxorubicin (DOXO) and cisplatin
(CDDP), are limited due to acquired drug resistance and
toxicities [1,2].
DOXO and CDDP are DNA-damaging drugs that exert
their anticancer actions via inhibition of cellular prolifera-
tion and induction of cell death by apoptosis [3,4]. The
tumor suppressor gene p53 plays a central role in
the anticancer actions of DNA-damaging agents. Loss of
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ging agents, such as DOXO and CDDP [5,6]. Identification
of anticancer agents that target p53 downstream genes via
p53-independent mechanisms is of major clinical rele-
vance, especially since p53 deficiency is a hallmark of
many different cancer types.
p73 is a member of the p53 gene family [7]. Unlike
p53 [8], p73 is rarely mutated or lost in cancers [9].
Although p53-deficient cancers are less responsive to
chemotherapy, they are typically not completely drug
resistant because other p53 family members, such as
p73, can replace p53 function in response to DNA
damage [9-11]. Since p73 is usually not mutated in
cancers and has been shown to regulate p53 target
genes in p53-deficient cancers, identification of antican-
cer agents that can activate p73 in p53-deficient cancers
will provide a chemotherapeutic approach for treatment
of drug-resistant p53 mutant cancers.
a-TEA (2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltride-
cyl) chroman-6-yloxyacetic acid, known as RRR-a-
tocopherol ether-linked acetic acid analog or RRR-a-toco-
pheryloxyacetic acid) is a nonhydrolyzable ether analog of
RRR-a-tocopherol [12]. a-TEA has been shown to be a
potent pro-apoptotic agent both in vitro and in vivo in
breast, prostate and ovarian cancer cells [12-20]. Recently,
a-TEA has been shown to delay tumor onset and to inhi-
bit the progression and metastatic spread in a clinically
relevant model of spontaneous mammary cancer, further
highlighting the translational potential of this anticancer
agent [14]. Mechanisms involved in a-TEA-induced apop-
tosis include activation of JNK/c-Jun, p73/NOXA and Fas/
death receptor-5 (DR5), and suppression of c-FLIP-L, sur-
vivin and phospho-Akt (pAkt) - leading to death receptor-
mediated caspase-8 activation and mitochondria-depen-
dent apoptosis [15-20].
Data presented here show that a-TEA in combination
with DOXO or CDDP significantly enhances apoptosis
of p53 mutant, triple-negative human breast cancer cells
by targeting p73-mediated p53-dependent pro-apoptotic
and anti-apoptotic genes via c-Abl, JNK and Yap signal-
ing pathways.
Materials and methods
Chemicals
a-TEA was made in-house as previously described [12].
DOXO and CDDP were purchased from Sigma (San
Diego, CA, USA). Phosphoinositide 3-kinase inhibitor
(wortmannin) was purchased from Cell Signaling Tech-
nology (Beverly, MA, USA).
Cell culture
p53 mutant, triple-negative human breast cancer cell lines
MDA-MB-231, BT-20 and MDA-MB-468 were purchased
from the American Type Culture Collection (Manassas,
VA, USA). MDA-MB-231 and BT-20 cells were cultured
in MEM media with 10% FBS, and MDA-MB-468 cells
were cultured in Dulbecco’s MEM media with 10% FBS.
All three p53 mutant TNBC cell lines (ER
-,P R -
-,H E R 2
-/
low)u s e di nt h e s es t u d i e sw e r eo r i g i n a l l yo b t a i n e df r o m
human samples so no isogenic counterparts expressing
wildtype p53, ER and progesterone receptor are available
for use as controls. For experiments, FBS was reduced to
2% to better mimic low in vivo serum exposure and cells
were allowed to attach overnight before treatment. a-TEA
(40 mM) was dissolved in ethanol as a stock solution.
Concentrations of ethanol used in vehicle treatments were
0.025 to 0.05% (v/v) to match the ethanol content in the
different final concentrations of a-TEA treatments.
DOXO and CDDP were dissolved in H2O.
Quantification of apoptosis
Apoptosis was quantified by annexin V-FITC/PI assays
following the manufacturer’s instructions. Fluorescence
was measured using fluorescence-activated cell sorter
analyses with a FACSCalibur flow cytometer, and data
were analyzed using CellQuest software (BD Biosciences,
San Jose, CA, USA). Cells displaying phosphatidylserine
on their surface (that is, positive for annexin-V fluores-
cence) were considered apoptotic.
Nuclear and cytoplasmic fractionation
Cytoplasmic and nuclear fractions were prepared as pre-
viously described [21]. Briefly, whole cell lysates were
centrifuged to obtain supernatant and pellet. The super-
natant was centrifuged again and the resulting superna-
tant was used as the cytosolic fraction. The pellet was
layered over a cushion of 1 ml sucrose buffer and cen-
trifuged. The final pellet, lysed using RIPA buffer, was
used as the nuclear fraction.
Western blot analyses
Whole cell protein lysates were prepared and western
blot analyses were conducted as described previously
[22]. Proteins (20 to 50 μg/lane) were separated by SDS-
PAGE and transferred to nitrocellulose (Optitran BA-S-
supported nitrocellulose; Schleicher and Schuell, Keene,
NH, USA). Antibodies to the following proteins were
used: poly(ADP-ribose) polymerase (PARP), Fas, Bcl-2,
Bax, total JNK and phospho-JNK (pJNK) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); p73 and NOXA
(Imgenex, San-Diego, CA, USA); and pYap (Ser-127),
Yap, p-cAbl (Tyr-245), c-Abl, pAkt (Ser-473), caspase-8,
caspase-9, DR5 and glyceraldehyde-3-phosphate dehy-
drogenase (Cell Signaling Technology).
RT-PCR detection of Fas, DR5, Bax, Noxa and Bcl-2 mRNA
expression
Total RNA was extracted using an RNA isolation kit (Qia-
gen Inc., Valencia, CA, USA). Semi-quantitative analyses
were conducted to detect Fas, DR5, Bax, Noxa and Bcl-2
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control. Total RNA was reverse transcribed to cDNA using
Superscript RTase (250 U; Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions. cDNA was used
per PCR reaction with Taq PCR Master Mix Kit (Qiagen
Inc.) plus 10 μM oligonucleotide primer pairs (Invitrogen).
The primer sequences are presented in Table 1.
RNA interference
A scrambled RNA duplex purchased from Ambion (Aus-
tin, TX, USA) that does not target any known mouse, rat
or human gene was used as the nonspecific negative con-
trol for interfering RNA (referred to as control siRNA).
Transfection of MDA-MB-231 cells with siRNA to p73,
c-Abl, JNK, Yap or control (Ambion) was performed in
100-mm cell culture dishes at a density of 2 × 10
6 cells/
dish using Lipofectamine 2000 (Invitrogen) and siRNA
duplex, resulting in a final siRNA concentration of 30
nM following the company’s instructions. After 1 day of
exposure to transfection mixture, the cells were re-cul-
t u r e di na1 0 0 - m md i s ha t2×1 0
6 cells/dish and incu-
bated for 1 day followed by treatment.
Statistical analysis
Apoptosis data were analyzed using one-way analysis of
variance followed by the Tukey test for comparison of
more than two treatments or a two-tailed Student t test
for comparison between two treatments to determine
statistical differences. Differences were considered statis-
tically significant at P < 0.05.
Results
a-TEA, DOXO and CDDP induce apoptosis in p53 mutant,
human TNBC cells
The sensitivity of three p53 mutant, TNBC lines (MDA-
MB-231, BT-20 and MDA-MB-468) to apoptosis
induced by a-TEA, DOXO and CDDP was evaluated by
determining half-maximal effective concentration values
for apoptosis (Table 2). Data show that MDA-MB-468
cells exhibit the most sensitive phenotype and MDA-
MB-231 cells exhibit the most resistant phenotype to
apoptosis induced by DOXO and CDDP among the
three cell lines. The sensitivity of the three cell lines to
a-TEA-induced apoptosis, however, is similar.
a-TEA cooperates with DOXO and CDDP to induce
apoptosis of p53 mutant, TNBC cells
Based on the half-maximal effective concentration values
for apoptosis presented in Table 2, the MDA-MB-231
and BT-20 cell lines that are more resistant to DOXO
and CDDP were chosen to study the combinational
effects of a-TEA + DOXO or a-TEA + CDDP on apop-
tosis induction. Data showed that a-TEA at 10 and
20 μM significantly enhanced apoptosis in combination
with DOXO and CDDP in MDA-MB-231 and BT-20
cells, respectively, in comparison with individual treat-
ments (Figure 1a to 1d). The mean combination index
for the combination of a-TEA + DOXO was 0.41 ± 0.07
and 0.53 ± 0.05 for MDA-MB-231 and BT-20 cells,
respectively (Table 3). The mean combination index for
the combination of a-TEA + CDDP was 0.45 ± 0.10
and 0.75 ± 0.08 in MDA-MB-231 and BT-20 cells,
respectively (Table 3). These data demonstrate that
combinations of a-TEA + DOXO or a-TEA + CDDP
synergistically induce apoptosis in both cell lines. Wes-
tern blot analyses show that a-TEA at 20 μMc o o p -
erates with DOXO and CDDP to induce elevated levels
of cleaved caspase-8, caspase-9, and PARP in both cell
lines (Figure 2a,b), indicating that apoptosis induced by
these combinations involves both caspase-8 and
caspase-9 activation.
p73 protein level is upregulated by a-TEA + DOXO or
a-TEA + CDDP combinations and is involved in
combination-induced apoptosis
Since DOXO and CDDP as well as a-TEA have been
shown to induce p73 upregulation in breast cancer
Table 1 Primer sequences
Gene Forward primer Reverse primer
Fas 5’-CAATGGGGATGAACCAGACTGC-3’ 5’-GGCAAAAGAAGAAGACAAAGCC-3’
DR5 5’-GCCTCATGGACAATGAGATAAAGGTGGCT-3’ 5’-CCAAATCTCAAAGTACGCACAAACGG-3’
Bax 5’-AGTAACATGGAGCTGCAGAGGATG-3’ 5’-AGGAGGCTTGAGGAGTCTCACC-3’
Noxa 5’-CGTGTGTAGTTGGCATCTCC-3’ 5’-AAGGAGTCCCCTCATGCAAG-3’
Bcl-2 5’-CCTGTGGATGACTGAGTACC-3’ 5’-GAGACAGCCAGGAGAAATCA-3’
b-actin 5’-GGCGGCACCACCATGTACCCT-3’’ 5’-AGGGGCCGGACTCGTCATACT-3’
Table 2 Half-maximal effective concentration values for
apoptosis
Cell line a-TEA (μM) DOXO (μM) CDDP (μM)
MDA-MB-231 41.7 46.5 70.8
BT-20 45.4 25.7 64.0
MDA-MB-468 35.4 8.5 40.7
Cells were treated with different concentrations of a-TEA, doxorubicin (DOXO),
and cisplatin (CDDP) for 24 hours. Apoptosis was determined by annexin V-
FITC/PI staining/fluorescence-activated cell sorter analysis as described in
Material and methods. The concentration that achieved 50% apoptosis (half-
maximal effective concentration) was determined using commercially
available software (Calcusyn; Biosoft, Manchester, UK).
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a-TEA + CDDP was investigated for ability to coopera-
tively enhance p73 protein expression. Single treat-
ments with DOXO, CDDP or a-TEA at sub-apoptotic
levels for 24 hours slightly increased p73 protein
expression above control levels, whereas combinations
at the same levels markedly enhanced p73 protein
expression in comparison with single treatments in
both MDA-MB-231 and BT-20 cells (Figure 3a,b).
siRNA to p73 significantly reduced the ability of com-
bination treatments to induce apoptosis as determined
by annexin V (Figure 3c) and PARP analyses (Figure
3d) in MDA-MB-231 cells. Western blot data show
that siRNA to p73 effectively silenced p73 protein
expression (Figure 3d). These data indicate that p73
activation by combination treatments is critical for
induction of cell death by apoptosis.
Combinations of a-TEA + DOXO or a-TEA + CDDP
upregulate pro-apoptotic and downregulate anti-
apoptotic mediators at both mRNA and protein levels
Published data show that p73 can regulate p53-depen-
dent genes in p53-deficient cells [11]. To better under-
stand the cellular events involved in p73-mediated
apoptosis in combination treatments, mRNA and pro-
tein expression of p53-mediated pro-apoptotic mediators
DR5, Fas, Bax, and Noxa, and anti-apoptotic mediator
Bcl-2 were examined. Combinations of a-TEA + DOXO
or a-TEA + CDDP enhanced DR5, Fas, Bax and Noxa
mRNA (Figure 4a,b) and protein expression (Figure 4c,
d), and decreased Bcl-2 mRNA (Figure 4a,b) and protein
expression (Figure 4c,d) in MDA-MB-231 and BT-20
cells. siRNA knockdown of p73 was performed to deter-
mine whether expression levels of these mediators were
regulated by p73. siRNA to p73 in MDA-MB-231 cells
Figure 1 a-TEA, doxorubicin and cisplatin induce apoptosis of p53 mutant, triple-negative human breast cancer cells. MDA-MB-231 and
BT-20 breast cancer cells were treated with different concentrations of doxorubicin (DOXO) or cisplatin (CDDP) alone or in combination with a-
TEA for 24 hours. Fluorescence-activated cell sorter/annexin V assays were used to determine the percentage of apoptotic cells (a), (b), (c), (d).
Data expressed as mean ± standard deviation from three independent experiments. *P <0.05, significantly different from control. **P <0.05,
significantly different from single treatments.
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ability of combinations to induce increased levels of DR5,
Fas, Bax and Noxa protein, as well as to decrease Bcl-2
protein levels (Figure 4e). These data suggest that combi-
nation treatments induce upregulation of pro-apoptotic
mediators and downregulation of an anti-apoptotic media-
tor in a p73-dependent manner in p53 mutant, TNBC
MDA-MB-231 and BT-20 cells. Recent studies in our
laboratory show that DR5 pro-apoptotic signaling contri-
butes to a-TEA-induced apoptosis [19,20]. To determine
whether DR5 contributes to combination treatment-
induced apoptosis, DR5 was functionally knocked-down
with siRNA. Data indicate that silencing DR5 protein
expression blocks combination-induced apoptosis as
determined by PARP cleavage (Figure 4f).
a-TEA cooperates with DOXO or CDDP to upregulate pc-
Abl and pJNK, upstream mediators of p73
Studies show that p73 can be upregulated upon DNA
damage via activation of c-Abl and JNK [23,24]. To
understand how p73 is activated by the combination
treatments, phosphorylated levels of c-Abl and JNK2/1
were examined. Combinations of a-TEA + DOXO or a-
TEA + CDDP induced increased levels of pc-Abl (Tyr-
245) and pJNK2/1 in both cell lines (Figure 5a,b). siRNA
knockdown of c-Abl or JNK significantly reduced the
ability of combination treatments to induce apoptosis in
MDA-MB-231 cells as determined by annexin V (Figure
5c) and PARP cleavage (Figure 5d). siRNA treatments
blocked the ability of combination treatments to
increase protein levels of p73 and blocked the ability of
combination treatments to increase protein levels of
DR5, Fas, Bax and Noxa, and to decrease the level of
Bcl-2 (Figure 5d). siRNA to c-Abl blocked the ability of
combination treatments to induce increased levels of
pJNK, whereas siRNA to JNK had no effect on the abil-
ity of combination treatments to induce increased levels
of pc-Abl (Tyr 245) (Figure 5d). These data show that
activation of p73 is mediated by c-Abl and JNK in the
combination treatments, and suggest that c-Abl, in part,
regulates the phosphorylation status of JNK.
Yap is involved in combination-induced apoptosis
Since Yap, a transcriptional co-activator Yes-asso-
ciated protein, can interact with p73, resulting in
enhanced p73 transcriptional activity [25] and stability
[26,27], we determined whether Yap contributes to
combination-induced apoptosis and increased p73
expression. siRNA knockdown of Yap significantly
reduced the ability of combination treatments to
induce apoptosis as measured by annexin V analyses
(Figure 6a) and western blot analyses of PARP clea-
vage (Figure 6b). siRNA to Yap effectively reduced
Yap protein levels and blocked combination treatment
effects on p73 protein expression, as well as combina-
tion effects on DR5, Fas, Bax, Noxa and Bcl-2 protein
expression (Figure 6b). These data show that Yap is a
key player in combination treatment-induced apopto-
sis mediated by p73.
Combination treatments induce Yap nuclear
translocation, which is associated with suppression of
phosphorylation of Akt and Yap
Yap activity can be regulated by c-Abl via phosphoryla-
tion of Yap at Tyr-357, leading to its stabilization and
higher affinity for p73 [28,29]. Furthermore, Yap can be
negatively regulated by Akt [29,30]. Akt induces Yap
phosphorylation at Ser-127, resulting in Yap cytosolic
localization via promoting Yap binding with 14-3-3,
resulting in inactivation of Yap [30]. Since a-TEA has
been shown to decrease pAkt in prostate cancer cells
[15], ovarian cancer cells [18], and breast cancer cells
(data not shown) we examined the effect of combination
treatments on Yap nuclear translocation, as well as on
pAkt and pYap expression.
Combination treatments of MDA-MB-231 cells
induced increased levels of Yap protein in the nuclear
fraction and reduced levels of Yap protein in the
cytoplasmic fraction. Histone 1 and glyceraldehyde-3-
phosphate dehydrogenase were used to evaluate the pur-
ity of nuclear and cytoplasmic fractions, respectively, and
served as lane load controls (Figure 7a). Furthermore,
data show that DOXO and CDDP increased pAkt and
pYap protein expression, while a-TEA cooperated with
DOXO or CDDP to suppress pAkt and pYap in MDA-
MB-231 (Figure 7b). These data suggest that Yap nuclear
Table 3 Combination index of apoptosis
Combination index
a
Cell line a-TEA:
drug
b
ED50 ED75 ED90 Mean ± SD
c
DOXO
MDA-
MB-231
20:1 0.48 0.40 0.35 0.41 ± 0.07 Synergism
d
BT-20 20:1 0.48 0.52 0.58 0.53 ± 0.05 Synergism
CDDP
MDA-
MB-231
2:1 0.55 0.44 0.36 0.45 ± 0.10 Synergism
BT-20 4:1 0.68 0.74 0.84 0.75 ± 0.08 Synergism
MDA-MB-231 and BT-20 breast cancer cells were treated with different
concentrations of a-TEA, doxorubicin (DOXO), and cisplatin (CDDP) alone and
in combination for 24 hours. Apoptosis was determined using annexin V-FITC/
PI staining/fluorescence-activated cell sorter assay as described in Material
and methods.
aFor each combination treatment, a combination index was
calculated using commercially available software (Calcusyn; Biosoft,
Manchester, UK).
bThe ratio for the concentrations used in combination
treatments was determined from the data in Figure 1.
cThe mean ± standard
deviation (SD) calculated from the combination index values of the effective
dose in 50% (ED50), the effective dose in 75% (ED75) and the effective dose in
90% (ED90) of the population.
dCombination index value: <1.0, synergism; 1.0,
additive effect; >1.0, antagonism.
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effects and that combination treatment downregulation
of pAkt correlates with decreased levels of pYap. To
assess the role of Akt in DOXO-induced and CDDP-
induced p73 protein expression, we examined the impact
of phosphoinositide 3-kinase/Akt inhibitor (wortmannin)
on DOXO-induced and CDDP-induced p73 protein
expression. Data show that wortmannin enhanced
DOXO-induced and CDDP-induced upregulation of p73
p r o t e i ne x p r e s s i o n( F i g u r e7c), indicating a role for Akt
in DOXO and CDDP increase in p73 expression. Data
also show that wortmannin blocked DOXO-induced and
CDDP-induced upregulation of pAkt and pYap (Figure
7c), suggesting that suppression of pAkt enhances
DOXO-induced and CDDP-induced p73 expression via
downregulation of pYap.
Figure 2 a-TEA cooperates with doxorubicin and cisplatin to induce cleavage of caspase-8, caspase-9 and poly(ADP-ribose)
polymerase. MDA-MB-231 and BT-20 cells were treated with doxorubicin (DOXO) or cisplatin (CDDP) alone or in combination with a-TEA for 24
hours. Western blot analyses were used to detect poly(ADP-ribose) polymerase (PARP), caspase-8, and caspase-9 cleavage (a), (b). Data are
representative of at least two independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEH, vehicle.
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p73 is an important target for treating p53 mutant can-
cers [10,31-33]. The novel findings in the present study
are as follows. First, a-TEA - a potent anticancer analog
of vitamin E - synergizes with DNA-damaging agents
DOXO and CDDP to induce apoptosis of human p53
mutant, triple-negative human breast cancer MDA-MB-
231 and BT-20 cells via targeting p73. Second, combina-
tion treatments result in p73-dependent upregulation of
pro-apoptotic DR5, Fas, Bax and Noxa, and downregula-
tion of anti-apoptotic mediator Bcl-2 - all of which are
p53-mediated apoptotic-related genes. Third, p73 and
p73-mediated apoptotic events are regulated by c-Abl,
JNK and Yap in combination treatments. Finally, a-TEA
downregulation of Akt partially contributes to p73
upregulation in combination treatments. Our data there-
fore, for the first time, identify a-TEA as a small bioac-
tive anticancer agent that regulates p53-mediated genes
via p53-independent mechanisms when combined with
DNA-damaging agents.
As a transcription factor, p73 shares structural and
functional similarities with p53 [9,32,33]. In cancer cells
that express wildtype p53, p73 has been reported to
cooperate with p53 to induce apoptosis [34]; whereas in
p53 mutant cancer cells, p73 has been reported to
induce apoptosis via activation of p53-inducible genes
[11,35]. Typically, p53 induces apoptosis via regulating
apoptosis-related genes such as DR5, Fas, Bax, Noxa
and Bcl-2 [36,37]. p73 is upregulated in response to a
subset of DNA-damaging agents, including DOXO,
Figure 3 p73 is upregulated by combination treatments and involved in combination-induced apoptosis. MDA-MB-231 and BT-20 cells
were treated with a-TEA, doxorubicin (DOXO) and cisplatin (CDDP) alone or in combination for 24 hours. Western blot analyses were performed
to detect protein levels of p73 with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as loading control (a), (b). MDA-MB-231 cells
were transfected with p73 siRNA or control siRNA for 2 days and treated with combinations of a-TEA + DOXO or a-TEA + CDDP for 24 hours.
Fluorescence-activated cell sorter/annexin V assays were used to determine the percentage of apoptotic cells (c). Western blot analyses were
used to verify the knockdown efficiency of p73 siRNA and the effect of p73 siRNA on combination-induced poly(ADP-ribose) polymerase (PARP)
cleavage (d). Data in (a), (b) and (d) representative of at least two independent experiments; data in (c) expressed as mean ± standard deviation
from three independent experiments. *P < 0.05, significantly different from control siRNA determined by t test.
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proteins. a-TEA cooperates with doxorubicin (DOXO) or cisplatin (CDDP) to upregulate mRNAs and proteins of the pro-apoptotic mediators
death receptor 5 (DR5), Fas, Bax, and Noxa, and downregulate anti-apoptotic Bcl-2 mRNA and protein, all of which are downstream targets of
p73. MDA-MB-231 and BT-20 cells were treated with DOXO or CDDP alone or in combination with a-TEA for 24 hours. mRNA levels of DR5, Fas,
Bax, Noxa and Bcl-2 were determined by RT-PCR with b-actin serving as loading control (a), (b). Protein levels of DR5, Fas, Bax, Noxa and Bcl-2
were determined by western blot analyses with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as loading control (c), (d). The
same treated samples as Figure 3d were used to detect the effect of siRNA to p73 on the combination-induced increase in protein levels of
DR5, Fas, Bax, Noxa and decrease in Bcl-2 by western blot analyses with GAPDH as loading control (e). MDA-MB-231 cells were transfected with
DR5 siRNA or control siRNA for 2 days and treated with combinations of a-TEA + DOXO or a-TEA + CDDP for 24 hours. Western blot analyses
were used to determine the effect of siRNA to DR5 on combination-induced poly(ADP-ribose) polymerase (PARP) cleavage and to verify the
knockdown efficiency of DR5 (f). Data representative of at least two independent experiments.
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mediated apoptosis-related genes have been identified to
b er e g u l a t e db yp 7 3 ,s u c ha sF a s ,B a x ,B i m ,N o x aa n d
Puma [17,39-41]. Whether DR5 is a direct target of p73,
however, is not well documented. It has been reported
that DR5 is regulated by p73 in H1299 human nonsmall
lung cancer cells [42]. El-Deiry and coworkers used a
high-throughput screen to identify small molecules that
Figure 5 a-TEA cooperates with doxorubicin or cisplatin to
upregulate pc-Abl and pJNK, which can serve as upstream
mediators of p73. a-TEA cooperates with doxorubicin (DOXO) or
cisplatin (CDDP) to upregulate pc-Abl and pJNK, which can serve as
upstream mediators of p73. MDA-MB-231 and BT-20 cells were
treated with DOXO or CIDDP alone or in combination with a-TEA
for 24 hours. Protein levels of pc-Abl (Tyr-245), total c-Abl (tc-Abl),
pJNK2/1, and total JNK2/1 (tJNK2/1) were determined by western
blot (a), (b). MDA-MB-231 cells were transfected with c-Abl and JNK
siRNAs, as well as control siRNA for 2 days and treated with a
combination of a-TEA + DOXO or a-TEA + CDDP for 24 hours.
Apoptosis was determined by annexin V/fluorescence-activated cell
sorter (c). Western blot analyses were used to verify the knockdown
efficiency of c-Abl and JNK siRNAs and the effect of c-Abl and JNK
siRNAs on combination-induced poly(ADP-ribose) polymerase (PARP)
cleavage, as well as p73 and p73-mediated death receptor 5 (DR5),
Fas, Bax, Noxa and Bcl-2 (d). Data in (a), (b), and (d) representative
of at least two independent experiments; data in (c) expressed as
mean ± standard deviation from three independent experiments.
*P <0.05, significantly different from control siRNA determined by
t test. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 6 Yap is involved in combination treatment-induced
apoptosis. MDA-MB-231 cells were transfected with Yap siRNA or
control siRNA for 2 days and treated with combinations for 24
hours. Apoptosis was determined by annexin V/fluorescence-
activated cell sorter (a). Western blot analyses were used to verify
the knockdown efficiency of Yap siRNA and the effect of Yap siRNA
on combination-induced poly(ADP-ribose) polymerase (PARP)
cleavage, as well as p73 and p73-mediated death receptor 5 (DR5),
Fas, Bax, Noxa and Bcl-2 (b). Data (a) expressed as mean ± standard
deviation from three independent experiments; data in (b)
representative of at least two independent experiments. *P <0.05,
significantly different from control siRNA determined by t test.
CDDP, cisplatin; DOXO, doxorubicin; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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of p53 target genes such as p21(Waf1), DR5 and TRAIL,
and induce apoptosis in p53-deficient colon cancer cells
[35]. Some of these compounds activated a p53 response
by increasing p73 expression, and knockdown of p73
with siRNA reduced their ability to activate p53 reporter
activity while other compounds acted in a p73-indepen-
dent fashion [35]. In addition, they characterized a deri-
vative of the plant alkaloid ellipticine as an anticancer
agent that induces p73 and DR5 protein expression in a
p53-deficient human colon carcinoma cell line [43].
Neither of these studies, however, showed direct evidence
that p73 was regulating DR5 transcription. To the best of
our knowledge, there is no direct evidence showing that
p73 regulates DR5 transcription other than the lung
cancer studies [42]. In addition, there is no evidence to
indicate that p73 transcriptionally regulates Bcl-2. The
present study thus demonstrates, for the first time, that
both DR5 and Bcl-2 are mediated at the transcriptional
level by p73 in p53 mutant, TNBC MDA-MB-231 and
BT-20 human breast cancer cells treated with a-TEA
combined with DOXO or CDDP as determined by
siRNA knockdown assays. Our previous data showed
that DR5 is involved in a-TEA-induced apoptosis since
siRNA knockdown of DR5 blocked a-TEA-induced
apoptosis in MCF-7 and MDA-MB-231 human breast
Figure 7 Combination treatments induce Yap nuclear translocation, associated with suppression of phosphorylation of Akt and Yap.
Isolated cytosolic and nuclear fractions from MDA-MB-231 cells treated with a-TEA + doxorubicin (DOXO) or a-TEA + cisplatin (CDDP) were
used to detect Yap tanslocation from cytosol to the nucleus by western blot analyses (a). MDA-MB-231 cells were treated with DOXO or CDDP
alone or in combination with a-TEA for 24 hours. Protein levels of pAkt and pYap were determined by western blot analyses with total Akt and
Yap serving as controls (b). MDA-MB-231 cells were pre-treated with Akt inhibitor wortmannin at 1 μM or dimethylsulfoxide for 2 hours followed
by treatments with DOXO or CDDP for 24 hours. Protein levels of p73, pAkt and pYap were determined by western blot analyses (c). Data are
representative of at least two independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEH, vehicle.
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necessary, at least in part, for apoptosis induced by
a-TEA combination treatments with DOXO or CDDP.
Besides transcriptionally activating p53-mediated
apoptotic genes, p73 has been reported to induce ER
stress via transactivation of Scotin [44]. Since DR5 and
Bcl-2 expression can be regulated by ER stress via
CHOP [45,46], and since a-TEA has been shown to
induce ER stress and CHOP expression [19], we cannot
rule out the possibility that p73 regulates DR5 and Bcl-2
via ER stress in combination treatments. Further studies
are needed to address this issue.
p73 is predominantly regulated at the post-translational
level in response to DNA-damaging agents. c-Abl and
JNK are activated by DNA-damaging agents and both are
involved in p73 activation [23,24]. DOXO and CDDP have
been shown to regulate p73 via c-Ab1 [23,28,29]. c-Abl
regulates p73 via different mechanisms; for example, c-Abl
can directly stabilize p73 via acetylation and phosphoryla-
tion of p73 [23,47], and can stabilize p73 and enhance p73
transcriptional activity via phosphorylation of Yap [28].
JNK has been reported to stabilize p73 via phosphorylation
of p73 [24] and via JNK phosphorylation/activation of
c-Jun [48]. In addition, JNK also activates p73 via enhan-
cing c-Abl nuclear translocation [49]. In untreated cells, c-
Abl is sequestered in the cytosol by 14-3-3 proteins. Upon
exposure of cells to DNA damaging agents, JNK is acti-
vated and phosphorylates 14-3-3, resulting in the release
of c-Abl into the nucleus, an event required for the induc-
tion of apoptosis in response to DNA-damaging agents
[49]. Published data [50] and the present data show that
c-Abl also regulates JNK via phosphorylation, suggesting
cross-talk between c-Abl and JNK.
Yap is a transcriptional coactivator, which can interact
with the p53 family member p73, resulting in an
enhancement of p73’s transcriptional activity [25,26] and
stability [27]. A potential mechanism of the p73 protein
stabilization was recently suggested by Levy and collea-
gues [27]. Namely, Yap competes with Itch, an E3 ubi-
quitin ligase involved in degradation of p73, for binding
to p73 at the PPXY motif. Furthermore, Yap activity can
be regulated by c-Abl via phosphorylation at Tyr-357,
leading to a more stable form of Yap that exhibits a
higher affinity to p73 [27]. Yap can be negatively regu-
lated by Akt [30,51]. Akt induces Yap phosphorylation
at Ser-127, resulting in Yap cytosolic localization since
phosphorylation of Yap at Ser-127 promotes Yap bind-
ing with 14-3-3 [30]. Yap activation can thus be regu-
lated in a positive manner by c-Abl and in a negative
manner by Akt. DNA damage can activate survival med-
iator Akt, resulting in reducing the anticancer efficacy of
DNA-damaging drugs. DOXO or CDDP induces activa-
tion of Akt in some cell lines [52,53]. Likewise, our data
show that DOXO and CDDP induce elevated levels of
pAkt not only in MDA-MB-231 cells (Figure 7), but
also in MCF-7, MDA-MB-453 and BT-20 cells (data not
shown). As expected, Akt inhibitors have been reported
to enhance the anticancer effect of DOXO in MDA-
MB-231 cells [54]. Data reported here show that Akt
inhibitor wortmannin enhanced DOXO-mediated and
CDDP-mediated increases in p73 protein expression,
which is associated with downregulation of pAkt and
pYap (Ser-127) in MDA-MB-231 cells. Taken together,
these data suggest that Akt activation upon DNA
damage may counteract p73 activation induced by JNK
and c-Abl via inhibition of Yap nuclear translocation.
Our data thus suggest that Yap nuclear translocation
plays an important role in p73 activation and that sup-
pression of pAkt and its inhibitory phosphorylation of
pYap contributes to enhanced Yap nuclear translocation
in combination treatments.
How a-TEA induces p73 protein expression is not
fully understood. We previously reported that JNK is
involved in regulation of p73 in a-TEA-induced apopto-
sis of human breast cancer cells [19]. In the present
study, we found that a-TEA also induces increased
levels of pc-Abl and Yap nuclear translocation, as well
as suppresses pAkt and pYap, suggesting that c-Abl and
Yap, as well as downregulation of pAkt/pYap, are also
involved in a-TEA-induced apoptosis. Noxa has been
identified as a downstream mediator of p73 in a-TEA-
induced apoptosis [17]. Whether other p53-mediated
genes, such as Fas, DR5, Bax and Bcl-2, are regulated by
73 following a-TEA treatment, however, has not been
investigated. Since recent data show that ER stress-
mediated CHOP contributes to a-TEA-induced upregu-
lation of DR5 and downregulation of Bcl-2 [19], it will
be important for future studies to address whether both
CHOP and p73 contribute to DR5 upregulation and
Bcl-2 downregulation in a-TEA-induced apoptosis.
Mechanisms mediating the combined anticancer effects
of a-TEA + DOXO or a-TEA + CDDP are diverse and
not completely understood. These studies identified p73
as a key player in combination treatment-induced apop-
tosis. In addition, data show that c-Abl, JNK and Yap
play roles in combination treatment-induced activation
of p73. It is important to note that although both a-TEA
and DNA-damaging drugs DOXO or CDDP induce
increased levels of pc-Ab1 and pJNK, only a-TEA and
the combination of a-TEA + DOXO or a-TEA + CDDP
induce Yap nuclear translocation, which is associated
with inhibition of pAkt (Ser-473) and Akt-phosphory-
lated pYap (Ser-127). Furthermore, a phosphoinositide 3-
kinase/Akt inhibitor was shown to enhance DOXO and
CDDP upregulation of p73, which was also associated
with downregulation of pAkt and pYap. Taken together,
these data suggest that downregulation of pAkt and the
pAkt-mediated inactive form of Yap play important roles
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ments. a-TEA thus cooperates with DOXO or CDDP to
induce p73 protein expression and apoptosis not only via
activation of c-Abl and JNK, but also via activation of
Yap, which may be regulated positively by c-Abl and
n e g a t i v e l yb yA k t .B a s e do np u b l i s h e dr e p o r t sa n dt h e
data presented here we proposed signaling events neces-
sary for combination treatment-induced apoptosis in p53
mutant, TNBC cells (Figure 8).
Conclusions
In summary, the data demonstrate that a-TEA, a small
bioactive lipid, cooperates with DNA-damaging agents
DOXO and CDDP to induce apoptosis in human breast
cancer cells via targeting p53-inducible apoptotic-related
genes in a p73-dependent manner. These studies high-
light the potential for activation of p73 as a promising
target for treatment of p53 mutant, TNBC and identify
a-TEA as an important candidate agent.
Figure 8 Proposed signaling pathways. Proposed pathways whereby the combination of a-TEA + doxorubicin (DOXO) or a-TEA + cisplatin
(CDDP) induces apoptosis in p53 mutant, triple-negative MDA-MB-231 and BT-20 human breast cancer cells. p73 can be activated via multiple
mechanisms and pathways, including: c-Abl and JNK can directly phosphorylate p73 to stabilize it; Yap in nucleus can bind with p73 to enhance
its transcriptional activity and stability; and p73 can be transcriptionally regulated (not studied here). Yap can be regulated in a positive manner
by c-Abl via phosphorylation enhancing its stability and transcriptional activity, and in a negative manner by Akt via inhibiting translocation of
Yap into the nucleus. c-Abl can directly phosphorylate JNK and JNK can enhance c-Abl nuclear translocation. Therefore, c-Abl, JNK and Yap play
positive roles and Akt plays a negative role in p73 activation. Our data show that DNA-damaging drugs DOXO and CDDP activated c-Abl and
JNK, but also activated Akt, which can counteract c-Abl and JNK effects on activation of p73. Combination treatments not only act cooperatively
to activate c-Abl and JNK, but also act cooperatively to inhibit pAkt and pYap (ser-127), leading to Yap nuclear translocation and p73 activation.
In summary, combinations of a-TEA + DOXO or a-TEA + CDDP act cooperatively to upregulate c-Abl/JNK, induce Yap nuclear translocation and
downregulate pAkt/pYap, leading to activation of p73 and upregulation of p73-mediated pro-apoptotic factors mediators, and downregulation
of Bcl-2, thereby restoring DOXO and CDDP chemotherapeutic potential in p53 mutant, triple-negative breast cancers. DR5, death receptor 5.
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